Aviragen

Aviragen cuts staff after pipeline busts

With two failed trials, Aviragen is looking at strategic alternatives to breathe new life into its business, and says it will cut its headcount by 25%.

Phil Taylor Apr 4, 2017 9:40am

Double-whammy for Aviragen as lead drug trial ends in failure

Feb 14, 2017 9:29am

Aviragen slumps as RSV drug fails midstage trial

Feb 2, 2017 8:36am